Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice

Hedda C Lamers, Erika Van Nieuwenhove, Sebastiaan J Vastert, Marc H A Jansen, Annet van Royen-Kerkhof, Joost F Swart, Sytze de Roock · 2025

Read Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice by Hedda C Lamers, Erika Van Nieuwenhove, Sebastiaan J Vastert, Marc H A Jansen, Annet van Royen-Kerkhof, Joost F Swart, Sytze de Roock (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750840.txt.

Description

Hedda Lamers and co-authors charted how new targeted drugs entered routine care for children with joint arthritis, in a 2025 study. Biologic and targeted synthetic drugs have widened options for juvenile idiopathic arthritis, the childhood form. The team pulled prescription records from the largest Dutch children's rheumatology center, covering 2012 to 2023.

First prescriptions numbered 672 for the targeted drugs and 720 for older standard ones, across 696 patients. One drug family, TNF-alpha blockers, took about 79 percent of the targeted share. Targeted prescribing grew over the period, and the authors align the shifts with approval dates and rule changes from the European regulator.

Catalog record

CREATORHedda C Lamers, Erika Van Nieuwenhove, Sebastiaan J Vastert, Marc H A Jansen, Annet van Royen-Kerkhof, Joost F Swart, Sytze de Roock
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12750840

Browse the full library · About the Tower of Babel